Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.57 |
| ▸ | YES1 | P07947 | 1/20 | 0.42 |
| ▸ | FGR | P09769 | 1/20 | 0.42 |
| ▸ | TEC | P42680 | 1/20 | 0.42 |
| ▸ | BMX | P51813 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10263489 | 0.92 | BTK (0.58) | BTKYES1FGRTECBMX | |
| SCHEMBL10263417 | 0.92 | BTK (0.61) | BTKYES1FGRTECBMX | |
| SCHEMBL10263444 | 0.92 | BTK (0.58) | BTKYES1FGRTECBMX | |
| SCHEMBL10262837 | 0.92 | BTK (0.58) | BTKYES1FGRTECBMX | |
| SCHEMBL10262634 | 0.91 | BTK (0.57) | BTKYES1FGRTECBMX | |
| SCHEMBL10268084 | 0.91 | BTK (0.58) | BTKYES1FGRTECBMX | |
| SCHEMBL10263467 | 0.90 | BTK (0.59) | BTK | |
| SCHEMBL608839 | 0.90 | BTK (0.69) | BTK | |
| SCHEMBL10264166 | 0.89 | BTK (0.58) | BTKYES1FGRTECBMX | |
| SCHEMBL10262466 | 0.89 | BTK (0.60) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040949-A1 | Inhibitors of Bruton's Tyrosine Kinase | BERTHEL STEVEN JOSEPH (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040949-A1 | Inhibitors of Bruton's Tyrosine Kinase | BTK, SYK, LYN | BTK 1/4885YES1 16/4885FGR 350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.